A phase I study of a novel human monoclonal antibody (mAb216) with chemotherapy for the treatment of patients with relapsed or refractory B-lineage acute lymphoblastic leukemia Liedtke, M., Twist, C., Bieber, M., Bhat, N., Teng, N. H., Coutre, S. AMER SOC HEMATOLOGY. 2007: 833A

View details for Web of Science ID 000251100803613